KBC Group
DYN icon

KBC Group’s Dyne Therapeutics DYN Stock Holding History

KBC Group’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$62K Buy
3,405
+270
+9% +$4.66K ﹤0.01% 1570
2025
Q4 		$61K Hold
3,135
– – ﹤0.01% 1564
2025
Q3 		$40K Hold
3,135
– – ﹤0.01% 1694
2025
Q2 		$30K Hold
3,135
– – ﹤0.01% 1701
2025
Q1 		$33K Hold
3,135
– – ﹤0.01% 1846
2024
Q4 		$74K Buy
3,135
+978
+45% +$28.9K ﹤0.01% 1709
2024
Q3 		$77K Buy
2,157
+751
+53% +$29.9K ﹤0.01% 1456
2024
Q2 		$50K Hold
1,406
– – ﹤0.01% 1611
2024
Q1 		$40K Buy
+1,406
New +$31.8K ﹤0.01% 1667

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

KBC Group's DYN Position: Q1 2026 in Review

KBC Group increased its Dyne Therapeutics (DYN) stake by 8.6% in Q1 2026, buying an estimated $4.66K and bringing the position to 3,405 shares worth $62K. The position accounts for ﹤0.01% of the portfolio, ranked #1570.

KBC Group first reported a position in DYN in Q1 2024 and has held it in 9 quarters since. The position peaked at $77K in Q3 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • KBC Group held 3,405 shares of Dyne Therapeutics worth $62K as of Q1 2026.
  • KBC Group bought 270 Dyne Therapeutics shares in Q1 2026, an estimated $4.66K.
  • Dyne Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1570 holding.
  • KBC Group first reported a position in Dyne Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • KBC Group's Dyne Therapeutics position peaked at $77K in Q3 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.